HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead’s twice-a-year PrEP medication lenacapavir, prompting …
Post
-
-
ERS 2026: BMI, type-2 inflammation, and asthma attack risk
On 7 September, at the European Respiratory Society (ERS) 2026 Annual Meeting, a group of investigators, which included both academic …
-
Staunch biotech competition spurs new secretive tactics, shifts investor approach
In recent years, the pharma and biotech landscape has experienced several seismic geopolitical and technological shifts, including China’s rise to …
-
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for …
-
ABEC to expand global manufacturing network with new Wilson facility
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process …
-
Encoded secures $275m for Dravet syndrome gene therapy
Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for …
-
Podcast: key readouts from ESC and ERS
It's conference season again. In this episode, the healthcare team rounds up the latest readouts and emerging themes from two …
-
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s …
-
HHS appoints permanent FDA CBER, CDER heads
The US Department of Health and Human Services (HHS) has selected four senior leaders to assume permanent positions in the …
-
Solstice Oncology secures $225m to drive porustobart’s development for cancer
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. The …
-
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for …
-
Why China’s rise needs to be taken with a pinch of salt
A closer look at the numbers that paint China as accelerating towards global biopharma dominance and you will find indications …
-
Pharma’s R&D, commercial approach shifts amid global policy evolution
A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch …
-
ERS 2026: GB-0895 clinical results show potential of next-gen anti-TSLP for asthma
On Sunday, September 6, at the European Respiratory Society (ERS) 2026 Annual Meeting, Generate: Biomedicinesinvestigators presented pharmacodynamics and safety results …
-
Moonwalk banks $70m to progress siRNA therapy for obesity
Moonwalk Biosciences has secured $70m in an oversubscribed, Eli Lilly-backed funding round to take its non-incretin obesity candidate to the …
